Therapeutic Strategies for Microvascular Dysfunction in Type 1 Diabetes

Description

The investigators will test the hypothesis that, in adults with type 1 diabetes (T1D), glucagon-like peptide-1 receptor agonism (GLP-1RA, i.e. dulaglutide) and exercise training each enhance insulin-mediated skeletal muscle microvascular perfusion via attenuating endothelial oxidative stress and thereby improving endothelial function.

Conditions

Diabetes Mellitus, Type 1, Endothelial Dysfunction

Talk to us

Study Overview

On this page

Study Details

Study overview

The investigators will test the hypothesis that, in adults with type 1 diabetes (T1D), glucagon-like peptide-1 receptor agonism (GLP-1RA, i.e. dulaglutide) and exercise training each enhance insulin-mediated skeletal muscle microvascular perfusion via attenuating endothelial oxidative stress and thereby improving endothelial function.

Therapeutic Strategies for Microvascular Dysfunction in Type 1 Diabetes

Therapeutic Strategies for Microvascular Dysfunction in Type 1 Diabetes

Condition
Diabetes Mellitus, Type 1
Intervention / Treatment

-

Contacts and Locations

Charlottesville

University of Virginia, Charlottesville, Virginia, United States, 22908

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * History of type 1 diabetes, duration \> 5 years
  • * Age 18-40 years
  • * HbA1c \< 8.5%
  • * BMI 19-34.9 kg/m2
  • * Using insulin for diabetes treatment only (multiple daily injections or insulin pump with or without sensor augmentation)
  • * On stable regimen of non-diabetic medications for the last 6 months
  • * All screening labs within normal limits or not clinically significant
  • * C-peptide \<0.6 ng/ml
  • * Pregnancy or currently breastfeeding
  • * Smoking history within 6 months
  • * History of microvascular (microalbuminuria, retinopathy, neuropathy) or macrovascular diabetes complications (coronary artery disease, stroke, peripheral vascular disease) as well as clinically significant cardiac arrhythmias or conduction disorders
  • * Taking vasoactive medications (i.e. calcium channel blockers, angiotensin-converting enzyme or renin inhibitors, angiotensin-receptor blockers, nitrates, alpha-blockers).
  • * Known hypersensitivity to perflutren (contained in Definity© contrast)
  • * Screening O2 saturation \<90%
  • * Musculoskeletal condition preventing participation in exercise testing or exercise training
  • * Acute or unstable disease other than T1D
  • * Hypoglycemia unawareness (based on Clarke's questionnaire)
  • * History of gastroparesis, severe gastroesophageal reflux, pancreatitis, personal or family history of medullary thyroid cancer or multiple endocrine neoplasia type 2
  • * Anemia (hemoglobin \<12 g/dL in women, hemoglobin \<13 g/dL in men), eosinophilia (absolute eosinophil count \>500 cells/microliter) leukopenia (total white blood cells \<4,000 cells/microliter)
  • * Diabetic ketoacidosis (DKA) on presentation to screening visits or study admission days
  • * Hospital admission for DKA within 1 year

Ages Eligible for Study

18 Years to 40 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

University of Virginia,

Kaitlin Love, MD, PRINCIPAL_INVESTIGATOR, Associate Professor - Endocrinology

Study Record Dates

2027-06-30